Reveals light-activated, nitric oxide-propelled nanosweepers for targeted thrombolysis and clot recurrence prevention, indicating a promising nonpharmaceutical therapy.
Traditional thrombolytic drugs offer limited outcomes due to short circulation half-life and low utilization. Herein, we have designed and constructed a biological mediator-propelled nanosweeper for highly efficient nonpharmaceutical thrombolysis and prevention of thrombus recurrence. Under the near-infrared light irradiation, the nanosweepers were activated to trigger nitric oxide (NO) release, which propelled the nanosweepers to penetrate deeply into the thrombus and resulted in enhanced site-pecific mechanical and photothermal thrombolysis. The experimental evidence confirmed that the ingenious nanosweeper displayed excellent site-specific thrombolytic efficacy even when compared with the clinical thrombolytic drug. In the meantime, as a biological mediator, the release of NO could effectively prevent thrombus recurrence in vivo. Overall, we anticipated that the nanosweeper would provide a promising strategy for the treatment of thrombi.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: